CombinatoRx News

On Friday's close, Zalicus ended the day up an impressive 13.90%. But for no reason? Hardly.

Breaking its previous mid-80 cent low, Zalicus has fallen, but on the heels of ZERO negative news.

's stock had its "buy" rating restated by analysts at Canaccord Genuity in a research report issued to clients and investors on Tuesday.

Zalicus opened at 0.8393 on Tuesday. Zalicus has a 52-week low of $0.82 and a 52-week high of $3.14. The company's market cap is $94.9 million.

BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of NEWLEAD HOLDINGS LTD , Zalicus Inc , FIRST TRUST LARGE CAP VALUE , Aercap Holdings NV , YUCHENG TECHNOLOGIES LTD , Green Plains Renewable Energy Inc and each have a high seasonal probability to go Down in the next weeks.

CAMBRIDGE, Mass. -- -- Zalicus Inc. a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases announced that Zalicus management will provide an overview of the Company at two upcoming investor conferences: Interested parties may access a live webcast of the ... (more)

Several Massachusetts pharmaceutical companies announced first quarter financial results Thursday, including increases in revenue from Repligen Corp.

Zalicus Advancing Z160, Its Novel, Oral N-type Calcium Channel Blocker, into Multiple Phase 2a Clinical Trials for the Treatment of Pain CAMBRIDGE, Mass.-- --May 2, 2012 - Zalicus Inc.